FIELD: medicine. SUBSTANCE: method involves determining alpha 1-antitripsine inhibitor (callicreine) activity in arterial and mixed venous blood serum, medium molecular mass contents and spontaneous luminescence in the whole blood. Respiratory distress syndrome risk coefficient is calculated for each item. EFFECT: enhanced effectiveness of early stage diagnosis.
Authors
Dates
1999-10-10—Published
1998-06-30—Filed